TVGN
Tevogen Bio Holdings Inc. NASDAQ Listed Jan 5, 2022$6.39
After hrs
$6.39
+0.00%
Mkt Cap $26.6M
52w Low $3.89
5.4% of range
52w High $50.50
50d MA $7.19
200d MA $12.61
P/E (TTM)
-1.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.4x
ROE
319.1%
P/FCF
-2.1x
RSI (14)
81.90
ATR (14)
$0.68
Beta
-0.30
50d MA
$7.19
200d MA
$12.61
Avg Volume
17.0K
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
15 INDEPENDENCE BOULEVARD, SUITE #210 · WARREN, NJ 07059 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -1.50 | -1.20 | +20.0% | 4.52 | -1.3% | -0.9% | -0.4% | +11.4% | +0.2% | +16.7% | — |
| Nov 14, 2025 | AMC | -0.06 | -0.03 | +50.7% | 20.86 | +0.7% | -7.2% | +5.7% | +9.8% | -8.0% | +9.1% | — |
| Aug 19, 2025 | AMC | -0.05 | -0.03 | +40.0% | 46.54 | -0.6% | -1.2% | -1.6% | +3.5% | -1.8% | +0.1% | — |
| May 14, 2025 | AMC | -0.05 | -3.21 | -6494.5% | 55.00 | -0.9% | +4.5% | -1.7% | +1.8% | +0.9% | +1.7% | — |
| Apr 2, 2025 | AMC | -0.03 | -2.60 | -7542.4% | 53.50 | -1.9% | -6.5% | +1.0% | +2.0% | -6.8% | +16.7% | — |
| Nov 19, 2024 | AMC | — | -1.74 | — | 68.00 | +21.3% | +4.4% | +15.5% | -8.5% | -5.3% | -5.6% | — |
| Aug 14, 2024 | AMC | — | -1.96 | — | 36.25 | -2.1% | -1.1% | -2.4% | -7.1% | -5.0% | +0.1% | — |
| May 27, 2024 | AMC | — | 3.96 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -1.12 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -1.23 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -7.98 | — | 534.00 | +0.0% | -0.1% | +1.2% | +0.1% | +0.0% | +1.1% | — |
| Mar 31, 2023 | AMC | — | -12.82 | — | 539.50 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | D. Boral Capital | Downgrade | Buy → Hold | — | $12.39 | $9.45 | -23.7% | -24.9% | -16.8% | -5.7% | +6.0% | +0.5% |
| Mar 3 | D. Boral Capital | Maintains | Buy → Buy | — | $12.44 | $12.51 | +0.6% | -0.4% | -24.9% | -16.8% | -5.7% | +6.0% |
| Nov 20 | D. Boral Capital | Maintains | Buy → Buy | — | $22.47 | $23.00 | +2.4% | -8.0% | +9.1% | -6.0% | +3.5% | +9.6% |
| Sep 4 | D. Boral Capital | Maintains | Buy → Buy | — | $44.50 | $45.00 | +1.1% | -1.2% | -1.5% | +1.5% | +0.6% | -1.4% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $47.42 | $47.26 | -0.3% | +1.6% | -3.4% | -1.2% | -1.6% | +3.5% |
| Aug 6 | D. Boral Capital | Maintains | Buy → Buy | — | $49.93 | $50.00 | +0.1% | -4.6% | -8.7% | +3.6% | +8.8% | -1.8% |
| Aug 4 | D. Boral Capital | Maintains | Buy → Buy | — | $50.00 | $50.50 | +1.0% | -0.7% | +0.6% | -4.6% | -8.7% | +3.6% |
| Jun 18 | D. Boral Capital | Maintains | Buy → Buy | — | $61.00 | $61.00 | +0.0% | -1.6% | +0.0% | -3.3% | +1.7% | -0.8% |
| Jun 10 | D. Boral Capital | Maintains | Buy → Buy | — | $55.00 | $58.00 | +5.5% | +12.7% | +8.1% | -5.2% | -2.4% | +2.4% |
| May 27 | D. Boral Capital | Maintains | Buy → Buy | — | $65.50 | $66.00 | +0.8% | -1.5% | +1.6% | +2.3% | -3.7% | +0.0% |
| May 12 | D. Boral Capital | Maintains | Buy → Buy | — | $54.50 | $55.50 | +1.8% | +9.2% | -2.5% | -5.2% | +4.5% | -1.7% |
| Apr 29 | D. Boral Capital | Maintains | Buy → Buy | — | $46.87 | $55.00 | +17.3% | +7.7% | +2.0% | -5.0% | +3.2% | +5.0% |
| Apr 21 | D. Boral Capital | Maintains | Buy → Buy | — | $48.98 | $48.00 | -2.0% | -4.8% | +3.9% | +5.2% | -1.0% | -1.8% |
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $53.00 | $53.00 | +0.0% | +0.9% | +3.7% | +0.0% | +5.4% | -0.9% |
No insider trades available.
8-K · 5.03
! Medium
Tevogen Bio Holdings Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jul 30
8-K
Tevogen Bio Holdings Inc. -- 8-K Filing
Tevogen Bio must achieve $50 million market capitalization or $15 million public float within specified compliance deadlines to maintain Nasdaq listing standards.
Apr 22
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TVGN's 8-K filing with limited disclosure details suggests a material event occurred, but vague filing suggests management may be withholding information, warranting investor caution on potential negative developments.
Mar 25
8-K · 7.01
! Medium
Tevogen Bio Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
Tevogen Bio announced a reverse stock split, a restructuring move typically signaling financial distress or an attempt to meet exchange listing requirements by consolidating outstanding shares.
Mar 4
8-K · 5.02
!!! Very High
Tevogen Bio Holdings Inc. -- 8-K 5.02: Executive Change
The departure of a key executive at Tevogen Bio creates uncertainty around leadership continuity and strategic direction, potentially pressuring the stock until a replacement is announced.
Feb 25
Institutional (13F) — Top 11
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 33,248 | $150K | New | Mar 2026 |
| 2 | Fmr Llc | 10,157 | $46K | New | Mar 2026 |
| 3 | Russell Investments Group, Ltd. | 5,806 | $26K | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 4,525 | $20K | New | Mar 2026 |
| 5 | Ubs Group Ag | 3,567 | $16K | New | Mar 2026 |
| 6 | Jpmorgan Chase & Co | 479 | $2K | New | Mar 2026 |
| 7 | Wells Fargo & Company/mn | 311 | $1K | New | Mar 2026 |
| 8 | Bnp Paribas Financial Markets | 282 | $1K | New | Mar 2026 |
| 9 | Barclays Plc | 249 | $1K | New | Mar 2026 |
| 10 | Royal Bank Of Canada | 121 | $1K | New | Mar 2026 |
| 11 | Cwm, Llc | 2 | $9 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 15
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Russell 2000 ETF | 10,303 | $47K | Mar 2026 |
| 2 | iShares Russell 2000 Growth ETF | 2,673 | $12K | Mar 2026 |
| 3 | Small Cap Index Fund | 2,669 | $12K | Mar 2026 |
| 4 | iShares Micro-Cap ETF | 2,429 | $11K | Mar 2026 |
| 5 | iShares Russell 2000 Value ETF | 2,037 | $9K | Mar 2026 |
| 6 | Fidelity Total Market Index Fund | 357 | $3K | May 2026 |
| 7 | Global X Russell 2000 ETF | 373 | $2K | Apr 2026 |
| 8 | Fidelity Series Total Market Index Fund | 300 | $2K | May 2026 |
| 9 | STATE STREET SMALL/MID CAP EQUITY INDEX PORTFOLIO | 178 | $805 | Mar 2026 |
| 10 | NVIT Small Cap Index Fund | 172 | $777 | Mar 2026 |
| 11 | BlackRock Small Cap Index V.I. Fund | 162 | $732 | Mar 2026 |
| 12 | DWS Small Cap Index VIP | 63 | $285 | Mar 2026 |
| 13 | State Street Total Return V.I.S. Fund | 18 | $81 | Mar 2026 |
| 14 | EQ/Franklin Small Cap Value Managed Volatility Portfolio | 3 | $14 | Mar 2026 |
| 15 | Russell 2000 Fund | 1 | $5 | Mar 2026 |
Valuation
Market Cap
$26.6M
Enterprise Value
$27.7M
P/E (TTM)
-1.09x
Forward P/E
—
PEG Ratio
-0.03x
P/B
—
P/S
—
P/FCF
-2.15x
EV/EBITDA
—
Shares Out
4.2M
Financials (TTM)
Revenue
$0
Net Income
-$21.4M
EBITDA
-$20.8M
Free Cash Flow
-$12.4M
Op Cash Flow
-$12.3M
EPS Basic
$-8.08
EPS Diluted
$-5.84
EPS Forward
$-10.14
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$4.4M
Total Liab.
$12.6M
Total Equity
-$8.2M
Cash
$0
LT Debt
$1.1M
Book Value/Sh
$-1.98
Debt/Equity
-0.38x
Current Ratio
0.22
Quick Ratio
0.22
Returns & Growth
ROE
319.1%
ROA
-599.5%
ROIC
3698.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
-72.7%
Price Returns
2W
+44.1%
1M
+24.4%
3M
-13.5%
6M
-52.9%
12M
-85.6%
Technicals
52W High
$50.50
52W Low
$3.89
50d MA
$7.19
200d MA
$12.61
RSI (14)
81.90
ATR (14)
$0.68
Beta
-0.30
Avg Volume
17K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 6:08am
· Source: financialmodelingprep.com